CT-868
A Study of CT-868 in Type 1 Diabetes Mellitus
Carmot Therapeutics, Inc · Phase 2 · Completed · Enrollment 111
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
- CT-868 Placebo
- Arm 2: CT-868 Titrated to 1.8 mg
- Arm 3: CT-868 Titrated to 4.1 mg
- Arm 4: CT-868 Titrated to 6.6 mg
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| CT-868 Low Dose | n/r | n/r | n/r | n/r |
| CT-868 Medium Dose | n/r | n/r | n/r | n/r |
| CT-868 High Dose | n/r | n/r | n/r | n/r |
| CT-868 Placebo | 2% | n/r | n/r | n/r |
| Arm 2: CT-868 Titrated to 1.8 mg | 6% | n/r | n/r | n/r |
| Arm 3: CT-868 Titrated to 4.1 mg | 15% | n/r | n/r | n/r |
| Arm 4: CT-868 Titrated to 6.6 mg | 15% | n/r | n/r | n/r |
Not shown
- CT-868 Low Dose: endpoint not reported
- CT-868 Medium Dose: endpoint not reported
- CT-868 High Dose: endpoint not reported